In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
David Feaster; Analyst; Raymond James & Associates, Inc. Andrew Liesch; Analyst; Piper Sandler & Co.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback